Vitamfero Successfully Secures Its Third Round Of Financing
VitamFero, a company developing novel anti-infective (notably anti-parasitics) prophylactic applications in animal health, has just secured a new capital increase in the amount of €2.7 million with GO CAPITAL (through the Ouest Ventures II fund), Pradeyrol Développement and Business Angels affiliated with Val de France Angels, accompanied by the original shareholders (i.e. CapDecisif Management, G1J Ile-de-France and individual investors) who thus renewed their confidence in, and support for, the company.
An officially-approved Genopole® firm established in 2005, VitamFero exploits major advances obtained and patented in partnership, notably, with the INRA (National Agronomic Research Institute, France) and François-Rabelais University of Tours in the field of anti-parasitic vaccines and veterinary neonatal immunostimulants, fields where needs remain largely unmet and where the market is estimated at several billion euros. VitamFero's technology is based on the development and molecular engineering of parasite strains (i.e. Toxoplasma gondii, Neospora caninum, ...) that are live and attenuated by targeted and total deletion of virulence genes.
This investment will allow VitamFero to pursue development of its products, notably in preventing ovine toxoplasmosis and bovine neosporosis, and to prepare their commercialization with the assistance of leading industry partners.
Member of Atlanpole Biotherapies, a French competitivity cluster, VitamFero is active in Molecular & Cellular Biology and Immunology in close collaboration with François-Rabelais University of Tours and the INRA. In addition to its laboratory in Tours (France), VitamFero will shortly have additional laboratories in Angers (France) where the company will consolidate its biopharmaceutical and clinical developmental activities and benefit from the internationally-recognized expertise of the University of Angers in biologic drug delivery.
For Pascal Breton, CEO of VitamFero, "This financing round is a key step in the development, growth and success of VitamFero. It bears recognition and validation of the work done by each of the members of our team, who, through commitment and sacrifice, has made it possible to achieve the key objectives we set for ourselves in the past months." "Over the last 24 months, VitamFero has reached major technical milestones that, particularly in terms of bio formulation of its vaccine strains, have convinced the new investors as well as the firm's industrial partners," said Catherine Boule, Partner at CapDecisif Management.
According to Leila Nicolas, Senior Business Analyst at GO CAPITAL, leader in this operation, "Led by a highly complementary management team of quality, VitamFero's project has persuaded and convinced us by its quality, relevance and international business prospects."
As for Alexandre Le Vert, (Director of Biotech Investments within the Pradeyrol Développement family holding), "It is with much interest and attention that we have followed VitamFero's progress for several years. We were able to gauge and assess the progress of the company and it is now with great confidence that we participate in its capital." Eventually, VitamFero aims to be in a major position in the attractive and very promising veterinary vaccines market.
Help employers find you! Check out all the jobs and post your resume.
An officially-approved Genopole® firm established in 2005, VitamFero exploits major advances obtained and patented in partnership, notably, with the INRA (National Agronomic Research Institute, France) and François-Rabelais University of Tours in the field of anti-parasitic vaccines and veterinary neonatal immunostimulants, fields where needs remain largely unmet and where the market is estimated at several billion euros. VitamFero's technology is based on the development and molecular engineering of parasite strains (i.e. Toxoplasma gondii, Neospora caninum, ...) that are live and attenuated by targeted and total deletion of virulence genes.
This investment will allow VitamFero to pursue development of its products, notably in preventing ovine toxoplasmosis and bovine neosporosis, and to prepare their commercialization with the assistance of leading industry partners.
Member of Atlanpole Biotherapies, a French competitivity cluster, VitamFero is active in Molecular & Cellular Biology and Immunology in close collaboration with François-Rabelais University of Tours and the INRA. In addition to its laboratory in Tours (France), VitamFero will shortly have additional laboratories in Angers (France) where the company will consolidate its biopharmaceutical and clinical developmental activities and benefit from the internationally-recognized expertise of the University of Angers in biologic drug delivery.
For Pascal Breton, CEO of VitamFero, "This financing round is a key step in the development, growth and success of VitamFero. It bears recognition and validation of the work done by each of the members of our team, who, through commitment and sacrifice, has made it possible to achieve the key objectives we set for ourselves in the past months." "Over the last 24 months, VitamFero has reached major technical milestones that, particularly in terms of bio formulation of its vaccine strains, have convinced the new investors as well as the firm's industrial partners," said Catherine Boule, Partner at CapDecisif Management.
According to Leila Nicolas, Senior Business Analyst at GO CAPITAL, leader in this operation, "Led by a highly complementary management team of quality, VitamFero's project has persuaded and convinced us by its quality, relevance and international business prospects."
As for Alexandre Le Vert, (Director of Biotech Investments within the Pradeyrol Développement family holding), "It is with much interest and attention that we have followed VitamFero's progress for several years. We were able to gauge and assess the progress of the company and it is now with great confidence that we participate in its capital." Eventually, VitamFero aims to be in a major position in the attractive and very promising veterinary vaccines market.
Help employers find you! Check out all the jobs and post your resume.